These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 27864787)

  • 1. Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
    Collins PD; Sattar N
    Curr Cardiol Rep; 2016 Dec; 18(12):133. PubMed ID: 27864787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.
    Dugré N; Lindblad AJ; Perry D; Allan GM; Braschi É; Falk J; Froentjes L; Garrison SR; Kirkwood JEM; Korownyk CS; McCormack JP; Moe SS; Paige A; Potter J; Thomas BS; Ton J; Young J; Weresch J; Kolber MR
    Can Fam Physician; 2023 Oct; 69(10):701-711. PubMed ID: 37833094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.
    Zhao Z; Du S; Shen S; Luo P; Ding S; Wang G; Wang L
    Medicine (Baltimore); 2019 Feb; 98(6):e14400. PubMed ID: 30732185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
    Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA
    Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin intolerance: diagnosis and remedies.
    Pirillo A; Catapano AL
    Curr Cardiol Rep; 2015 May; 17(5):27. PubMed ID: 25894795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
    Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
    Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.
    Zafrir B; Jain M
    Cardiovasc Drugs Ther; 2014 Aug; 28(4):361-77. PubMed ID: 24952127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid lowering for secondary prevention of cardiovascular disease in older adults.
    Thomas JE; Tershakovec AM; Jones-Burton C; Sayeed RA; Foody JM
    Drugs Aging; 2010 Dec; 27(12):959-72. PubMed ID: 21087066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Optimal lipid treatment: possibilities and current limitations].
    Klose G
    Internist (Berl); 2011 Mar; 52(3):328-35. PubMed ID: 21331642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of conventional lipid-lowering therapy on circulating levels of PCSK9: protocol for a systematic review and meta-analysis of randomised controlled trials.
    Luo J; Huang T; Xu R; Wang X; Yang Y; Li L; Zhang X; Zhang Y; Yang R; Wang J; Yang H; Ma Y; Yang B; Wang T; Jiao L
    BMJ Open; 2022 Sep; 12(9):e061884. PubMed ID: 36691198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
    Reklou A; Katsiki N; Karagiannis A; Athyros V
    Curr Vasc Pharmacol; 2020; 18(1):38-42. PubMed ID: 30663570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrates and niacin: is there a place for them in clinical practice?
    Wierzbicki AS; Viljoen A
    Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
    Mathew RO; Rosenson RS; Lyubarova R; Chaudhry R; Costa SP; Bangalore S; Sidhu MS
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):479-489. PubMed ID: 32556851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.